Role of botulinum toxin in hand and upper limb disorders relevant to hand therapy

Hand Therapy

Volumn 14, Issue 2, 2009, Pages 32-38

  Keir, James ^a   Giele, Henk P ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Botulinum toxin; hand disorders; hand therapy; upper limb therapy

Indexed keywords

EID: 84888279912     PISSN: 17589983     EISSN: 17589991     Source Type: Journal    
DOI: 10.1258/ht.2009.009010     Document Type: Review

References (65)

1. Burke GS. Notes on the Bacillus botulinus. J Bacteriol 1919; 4: 555–65
2. Jankovic J, Hallett M. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, 1994
3. DePaiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 53: 1439–46
4. DeMatteo C, Bain JR, Galea V, Gjertsen D. Botulinum toxin as an adjunct to motor learning therapy and surgery for obstetrical brachial plexus injury. Dev Med Child Neurol 2006; 48: 245–52
5. Heise CO, Gonçalves LR, Barbosa ER, Gherpelli JL. Botulinum toxin for treatment of cocontractions related to obstetrical brachial plexopathy. Arq Neuropsiquiatr 2005; 63: 588–91
6. Basciani M, Intiso D. Botulinum toxin type-A and plaster cast treatment in children with upper brachial plexus palsy. Pediatr Rehabil 2006; 9: 165–70
7. Odderson IR. Hyperhydrosis treated by botulinum A exotoxin. Dermatol Surg 1998; 24: 1237
8. Naumann M, Flachenecker P, Bröcker EB, et al. Botulinum toxin for palmar hyperhydrosis. Lancet 1997; 349: 252
9. Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhydrosis of the palms. Br J Dermatol 1997; 136: 548
10. Hans-Juergen B, Vollert B. Intravenous egional anaesthesia (Bier’s Block) for botulinum toxin therapy of palmar hyperhydrosis is safe and effective. Dermatol Surg 2002; 28: 671–2
11. Baumann L, Frankel S, Welsh E, et al. Cryoanalgesia with dichlorotetraflouroethane lessens the pain of botulinum toxin injections for the treatment of palmar hyperhydrosis. Dermatol Surg 2003; 29: 1057–60
12. Atkins JL, Butler P. Hyperhydrosis: a review of current management. Plast Reconstr Surg 2002; 110: 222–8
13. Davarian S, Kalantari KK, Rezasoltani A, Rahimi A. Effect and persistency of botulinum toxin iontophoresis in the treatment of palmar hyperhidrosis. Australas J Dermatol 2008; 49: 75–9
14. Saadia D, Voustianiouk A, Wang A, Kaufmann H. Botulinum toxin type A in primary palmar hyperhydrosis: randomised, single-blind, two dose study. Neurology 2001; 57: 2095–9
15. Bhakta BB, Cozens JA, Bamford JM, et al. Use of botulinum toxin in stroke patients with severe upper limb spaticity. J Neurol Neurosurg Psychiatry 1996; 61: 30–5
16. Borg-Stein J, Pine ZM, Miller JR, et al. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil 1993; 72: 364–8
17. Chutorian A, Root L. Management of spasticity in children with botulinum A toxin. Int Pediatr 1994; 9: 35–43
18. Cosgrove AP, Graham HK. Botulinum toxin A in the management of cerebral palsy. J Bone Jt Surg (Am) 1992; 74(suppl):135–6
19. Koman LA, Mooney JF 3rd, Smith B, et al. Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489–95
20. Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 1996; 77: 717–21
21. Simpson DM, Alexander DN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306–10
22. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990; 28: 512–5
23. Yablon SA, Agana BT, Ivanhoe CB, et al. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology 1996; 47: 939–44
24. Brashear A, Gordon MF, Elovic E Intramuscular injection of botulinum toxin for the treatment of wrist finger spasticity after a stroke. N Engl J Med 2002; 347: 395–400
25. Yang TF, Fu CP, Kao NT, et al. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 2003; 82: 284–9
26. Fehlings D, Rand M, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000; 137: 300–3
27. Sätilä H, Kotamäki A, Koivikko M, Autti-Rämö I. Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases. Pediatr Rehabil 2006; 9: 247–58
28. Francisco GE, Ivanhoe CB. Pharmocologic management of spasticity in adults with brain injury. Phys Med Rehabil North Am 1997; 8: 707–31
29. Lamid S, Ghatit AZ. Smoking, spasticity and pressure sores in spinal cord injury patients. Am J Phys Med 1983; 62: 300–6
30. Miscio G, Del Conte C, Pianca D, et al. Botulinum toxin in post-stroke patients: stiffness modifications and clinical implications. J Neurol 2004; 251: 189–96
31. Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Neurol Sci 2005; 26: 32–9
32. Jahangir AW, Tan HJ, Norlinah MI, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med J Malaysia 2007; 62: 319–22
33. Levy CE, Giuffrida C, Richards L, Wu S, Davis S, Nadeau SE. Botulinum toxin a, evidence-based exercise therapy, and constraint-induced movement therapy for upper-limb hemiparesis attributable to stroke: a preliminary study. Am J Phys Med Rehabil 2007; 86: 696–706
34. Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002; 16: 654–60
35. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009; 41: 13–25
36. Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004; 4: CD003469
37. Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pract 1989; 43: 401–3
38. Hughes AJ. Botulinum toxin in clinical practice. Drugs 1994; 48: 888–93
39. Yang TF, Chan RC, Chuang TY, et al. Treatment of cerebral palsy with botulinum toxin: evaluation with gross motor function measure. J Formos Med Assoc 1999; 98: 832–6
40. Rösblad B, Andersson G, Pettersson K. Effects of botulinum toxin type A and a programme of functional activity to improve manual ability in children and adolescents with cerebral palsy. Scand J Plast Reconstr Surg Hand Surg 2007; 41: 250–8
41. Wall SA, Chait LA, Temlett JA, Perkins B, Hillen G, Becker P. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg 1993; 46: 703–6
42. Wallen M, O’Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil 2007; 88: 1–10
43. Speth LA, Leffers P, Janssen-Potten YJM, Vles JSH. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 2005; 47: 468–73
44. Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol 2001; 8(Suppl 5):145–9
45. Chait LA, de Aguiar G, Theron A, Bleloch S. The role of botulinum toxin in treating cerebral palsy hands. Curr Opin Orthop 2002; 13: 251–5
46. Sheean G. Restoring balance in focal limb dystonia with botulinum toxin. Disabil Rehabil 2007; 29: 1778–88
47. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer’s cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007; 78: 264–70
48. Schuele S, Jabusch HC, Lederman RJ, Altenmüller E. Botulinum toxin injections in the treatment of musician’s dystonia. Neurology 2005; 64: 341–3
49. Koller WC, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986; 36: 1001–4
50. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Ann Neurol 1994; 35: 717–23
51. Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology 1991; 41: 1185–90
52. Trosch RM, Pullman SC. Botulinum A toxin injections of the treatment of hand tremor. Mov Disord 1994; 9: 601–9
53. Henderson JM, Ghika JA, van Melle G, et al. Botulinum toxin A in nondystonic tremors. Eur Neurol 1996; 36: 29–35
54. Pullman SL, Greene P, Fahn S, et al. Approach to the treatment of limb disorders with botulinum toxin A: experience with 187 patients. Arch Neurol 1996; 53: 617–24
55. Jankovic J, Schwartz K, Clemence W, et al. A randomised double-blind, placebo controlled study to evaluate botulinum toxin A in essential hand tremor. Mov Disord 1996; 11: 250–6
56. Brin MF, Lyons KE, Doucette J, et al. A randomised, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56: 1523–8
57. Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev Neurother 2007; 7: 637–47
58. Müller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 2002; 249: 300–4
59. Tuzuner S, Balci N, Ozkaynak S. Results of zone II flexor tendon repair in children younger than age 6 years: botulinum toxin type A administration eased cooperation during the rehabilitation and improved outcome. J Pediatr Orthop 2004; 24: 629–33
60. Kossintseva I, Barankin B. Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. J Cutan Med Surg 2008; 12: 189–93
61. Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 2007; 119: 217–26
62. Wong SM, Hui AC, Tong PY, Poon DW, Yu E. Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2005; 143: 793–7
63. Hayton MJ, Santini AJ, Hughes PJ, Frostick SP, Trail IA, Stanley JK. Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Jt Surg Am 2005; 87: 503–7
64. Oskarsson E, Piehl Aulin K, Gustafsson BE, Pettersson K. Improved intramuscular blood flow and normalized metabolism in lateral epicondylitis after botulinum toxin treatment. Scand J Med Sci Sports 2008; 64: Epub ahead of print
65. Breuer B, Sperber K, Wallenstein S, et al. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med 2006; 7: 16–20